# Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer

> **NCT06039202** · PHASE2 · UNKNOWN · sponsor: **Holy Stone Healthcare Co., Ltd** · enrollment: 100 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** CA102N
- **DRUG:** TAS-102
- **BIOLOGICAL:** Bevacizumab

## Key facts

- **NCT ID:** NCT06039202
- **Lead sponsor:** Holy Stone Healthcare Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01
- **Primary completion:** 2025-02
- **Final completion:** 2025-10
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06039202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06039202, "Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06039202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*